At the moment, RevMed remains keenly focused on its mission to bring daraxonrasib to the masses and continue developing new medicines that target RAS. (Darren Incorvaia) This year’s meeting of the ...
Real-world data show that GLP-1 receptor agonists (GLP-1s) may reduce metastatic progression of certain obesity-related cancers, namely lung, breast, colorectal, and liver cancers. In addition, GLP-1 ...
Renovus Capital Partners Ranked #1 on HEC-Dow Jones Worldwide Performance Ranking of Small-Cap Private Equity Funds for Fourth Straight Year Renovus Capital Partners (“Renovus”), a Philadelphia-area ...
Kestrel today announced that the first patient has been dosed in its phase 1 trial of KST-6051, an oral small molecule meant to inhibit multiple different kinds of KRAS mutations. (iStock / Getty ...
Robust monotherapy efficacy in KRAS G12X NSCLC: 62% uORR in 2L+ and 75% uORR in post-ICI/platinum 2/3L at 16-32 mg QD PAD, and 64% uORR in 2L+ at 24-32 mg QD RDE Robust monotherapy efficacy in 2L KRAS ...
PARIS — RAS Luxury Skincare, the Indian farm-to-face brand, closed a 65 Crores, or $7.5 million, Series B funding round led by Dabur Ventures. Dabur Ventures is the venture arm of the largest ...
Clinical benefits regarding asthma stability were observed across all body mass index categories, including overweight, obese, and morbidly obese cohorts. Treatment with glucagon-like peptide-1 ...
About The Study: In this systematic review and meta-analysis, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) produced greater weight loss among women than men; however, their efficacy was ...
A comprehensive meta-analysis of 91 clinical trials involving more than 100,000 patients showed no increased risk for suicidal ideation or other psychiatric adverse events with GLP-1 receptor agonist ...
The resulting study, published in the medical journal JAMA Network Open, looked at the health data of 21,790 veterans with type 2 diabetes to compare three different GLP-1 RAs - liraglutide, ...
Patients with type 2 diabetes and inflammatory arthritis who received GLP-1 RAs had lower rates of hypoglycemia, serious infections, and acute kidney injury vs those receiving SGLT2 inhibitors.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results